Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure

Further Publications

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Am Heart J.

Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, de Souza AS, de Albuquerque DC, Mazza L, Santos MF, Salvador NZ, Gibson CM, Granger CB, Alexander JH, de Souza OF

doi: 10.1016/j.ahj.2020.05.002.

Heart FailureHypertension

Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)

Circ Heart Fail.

Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD

doi: 10.1161/CIRCHEARTFAILURE.

Atrial FibrillationHeart, Artery and Coronary DiseasesHeart FailureMyocardial Infarction

Lower In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

J Am Heart Assoc

Tamaki Y, Yaku H, Morimoto T, Inuzuka Y, Ozasa N, Yamamoto E, Yoshikawa Y, Miyake M, Kondo H, Tamura T, Kitai T, Iguchi M, Nagao K, Nishikawa R, Kawase Y, Morinaga T, Kawato M, Toyofuku M, Sato Y, Kuwahara K, Nakagawa Y, Kato T, Kimura T, KCHF Study Investigators.

doi: 10.1161/JAHA.120.020012

Heart Failure

Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality

JACC Heart Fail.

Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P

doi: 10.1016/j.jchf.2019.07.010.

Heart Failure

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Eur Heart J.

Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, Rienstra M, Friedrich AW, Samani NJ, Ng LL, Dickstein K, Lang CC, Filippatos G, Anker SD, Ponikowski P, Metra M, van Veldhuisen DJ, Voors AA

doi: 10.1093/eurheartj/ehaa373.

Hypertension

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System

J Am Heart Assoc

An J, Wei R, Zhou H, Luong TQ, Gould MK, Mefford MT, Harrison TN, Creekmur B, Lee MS, Sim JJ, Brettler JW, Martin JP, Ong-Su AL, Reynolds K

doi: 10.1161/JAHA.120.019669

Heart Failure

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

ESC Heart Fail.

Kapłon-Cieślicka A, Laroche C, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Maggioni AP, Hage C, Lara-Padrón A, Fucili A, Drożdż J, Seferovic P, Rosano GMC, Mebazaa A, McDonagh T, Lainscak M, Ruschitzka F, Lund LH, Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators

doi: 10.1002/ehf2.12817.

Atrial FibrillationHeart Failure

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure

J Am Coll Cardiol.

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group

doi: 10.1016/j.jacc.2017.04.001.

Atrial FibrillationHeart Failure

Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.

JACC Heart Fail.

Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondésert B, Dyrda K, Rivard L, Andrade JG, Macle L, Guerra PG, Thibault B, Dubuc M, Khairy P

doi: 10.1016/j.jchf.2016.10.015.

Related content

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Lower In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure

Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.